Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 140

1.

Klinefelter syndrome: From pediatrics to geriatrics.

Shiraishi K, Matsuyama H.

Reprod Med Biol. 2018 Dec 8;18(2):140-150. doi: 10.1002/rmb2.12261. eCollection 2019 Apr. Review.

2.

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer.

Sakamoto S, Maimaiti M, Xu M, Kamada S, Yamada Y, Kitoh H, Matsumoto H, Takeuchi N, Higuchi K, Uchida HA, Komiya A, Nagata M, Nakatsu H, Matsuyama H, Akakura K, Ichikawa T.

J Clin Med. 2019 Apr 11;8(4). pii: E489. doi: 10.3390/jcm8040489.

3.

Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.

Mikami S, Mizuno R, Kondo T, Shinohara N, Nonomura N, Ozono S, Eto M, Tatsugami K, Takayama T, Matsuyama H, Kishida T, Oya M; Japanese Society of Renal Cancer.

Cancer Sci. 2019 Apr 10. doi: 10.1111/cas.14019. [Epub ahead of print]

4.

Risk stratification by means of biological age-related factors better predicts cancer-specific survival than chronological age in patients with upper tract urothelial carcinoma: a multi-institutional database study.

Inamoto T, Matsuyama H, Ibuki N, Komura K, Fujimoto K, Shiina H, Sakano S, Nagao K, Miyake M, Yasumoto H, Azuma H; Nishinihon Uro-Oncology Collaborative Group.

Ther Adv Urol. 2018 Nov 11;10(12):403-410. doi: 10.1177/1756287218811050. eCollection 2018 Dec.

5.

Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma.

Nagao K, Shinohara N, Smit F, de Weijert M, Jannink S, Owada Y, Mulders P, Oosterwijk E, Matsuyama H.

BMC Cancer. 2018 Nov 15;18(1):1114. doi: 10.1186/s12885-018-5060-8.

6.

Transperitoneal versus retroperitoneal laparoscopic adrenalectomy for large pheochromocytoma: Comparative outcomes.

Shiraishi K, Kitahara S, Ito H, Oba K, Ohmi C, Matsuyama H.

Int J Urol. 2019 Feb;26(2):212-216. doi: 10.1111/iju.13838. Epub 2018 Nov 14.

PMID:
30430653
7.

Effects of medical comorbidity on male infertility and comorbidity treatment on spermatogenesis.

Shiraishi K, Matsuyama H.

Fertil Steril. 2018 Nov;110(6):1006-1011.e2. doi: 10.1016/j.fertnstert.2018.07.002.

PMID:
30396536
8.

Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan.

Ito K, Mikami S, Tatsugami K, Masumori N, Shinohara N, Kondo T, Nakanishi S, Nagashima Y, Eto M, Kamba T, Kuroda N, Tomita Y, Matsuyama H, Onishi T, Tsushima T, Nakazawa H, Oya M, Ozono S, Naito S, Asano T.

Clin Genitourin Cancer. 2018 Dec;16(6):e1201-e1214. doi: 10.1016/j.clgc.2018.07.028. Epub 2018 Aug 11.

PMID:
30224330
9.

Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study.

Nakai Y, Inoue K, Tsuzuki T, Shimamoto T, Shuin T, Nagao K, Matsuyama H, Oyama M, Furuse H, Ozono S, Miyake M, Fujimoto K.

Int J Urol. 2018 Aug;25(8):723-729. doi: 10.1111/iju.13718. Epub 2018 Jul 12.

PMID:
29999205
10.

Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan.

Kojima T, Nishiyama H, Ozono S, Hinotsu S, Keino N, Yamaguchi A, Sakai H, Enomoto Y, Horie S, Fujimoto K, Matsuyama H, Okamura T, Kanimoto Y, Oya M, Nonomura N, Naito S, Akaza H.

Int J Clin Oncol. 2018 Dec;23(6):1140-1147. doi: 10.1007/s10147-018-1311-6. Epub 2018 Jul 3.

PMID:
29971622
11.

[Successful Treatment of Peritoneal Dissemination Recurrence with Axitinib in Papillary Renal Cell Carcinoma : A Case Report].

Mori J, Nakayama Y, Hiragino T, Matsuyama H.

Hinyokika Kiyo. 2018 Feb;64(2):45-48. doi: 10.14989/ActaUrolJap_64_2_45. Japanese.

12.

Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma.

Yamamoto Y, Tsunedomi R, Fujita Y, Otori T, Ohba M, Kawai Y, Hirata H, Matsumoto H, Haginaka J, Suzuki S, Dahiya R, Hamamoto Y, Matsuyama K, Hazama S, Nagano H, Matsuyama H.

Oncotarget. 2018 Mar 30;9(24):17160-17170. doi: 10.18632/oncotarget.24715. eCollection 2018 Mar 30.

13.

Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI) study.

Nakajima K, Kaneko G, Takahashi S, Matsuyama H, Shiina H, Ichikawa T, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Mizokami A; PROSTAT-BSI Investigators.

Int J Urol. 2018 May;25(5):492-499. doi: 10.1111/iju.13556. Epub 2018 Apr 6.

14.

Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?

Nagao K, Matsuyama H, Matsumoto H, Nasu T, Yamamoto M, Kamiryo Y, Baba Y, Suga A, Tei Y, Yoshihiro S, Aoki A, Shimabukuro T, Joko K, Sakano S, Takai K, Yamaguchi S, Akao J, Kitahara S; Yamaguchi Uro-Oncology Group.

Int J Clin Oncol. 2018 Aug;23(4):757-764. doi: 10.1007/s10147-018-1272-9. Epub 2018 Mar 27.

15.

The systemic inflammation-based Glasgow Prognostic Score as a powerful prognostic factor in patients with upper tract urothelial carcinoma.

Inamoto T, Matsuyama H, Sakano S, Ibuki N, Takahara K, Komura K, Takai T, Tsujino T, Yoshikawa Y, Minami K, Nagao K, Inoue R, Azuma H.

Oncotarget. 2017 Nov 23;8(68):113248-113257. doi: 10.18632/oncotarget.22641. eCollection 2017 Dec 22.

16.

Extracellular miR-224 as a prognostic marker for clear cell renal cell carcinoma.

Fujii N, Hirata H, Ueno K, Mori J, Oka S, Shimizu K, Kawai Y, Inoue R, Yamamoto Y, Matsumoto H, Shimabukuro T, Udoh K, Hoshii Y, Dahiya R, Matsuyama H.

Oncotarget. 2017 Nov 15;8(66):109877-109888. doi: 10.18632/oncotarget.22436. eCollection 2017 Dec 15.

17.

Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.

Miyake M, Tatsumi Y, Matsumoto H, Nagao K, Matsuyama H, Inamoto T, Azuma H, Yasumoto H, Shiina H, Fujimoto K; Nishinihon Uro-Oncology Collaborative Group.

BJU Int. 2018 May;121(5):764-773. doi: 10.1111/bju.14111. Epub 2018 Jan 21.

18.

Biological Behavior and Long-Term Outcomes of Carcinoma In Situ in Upper Urinary Tract Managed by Radical Nephroureterectomy.

Inamoto T, Matsuyama H, Ibuki N, Komura K, Takahara K, Fujimoto K, Shiina H, Sakano S, Nagao K, Miyake M, Tatsumi Y, Yasumoto H, Azuma H; Nishinihon Uro-Oncology Collaborative Group.

J Urol. 2018 Apr;199(4):933-939. doi: 10.1016/j.juro.2017.10.019. Epub 2017 Oct 14.

PMID:
29037861
19.

Germline DNA copy number variations as potential prognostic markers for non-muscle invasive bladder cancer progression.

Yamamoto Y, Suehiro Y, Suzuki A, Nawata R, Kawai Y, Inoue R, Hirata H, Matsumoto H, Yamasaki T, Sasaki K, Matsuyama H.

Oncol Lett. 2017 Jul;14(1):1193-1199. doi: 10.3892/ol.2017.6233. Epub 2017 May 24.

20.

The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.

Nagao K, Hara T, Nishijima J, Shimizu K, Fujii N, Kobayashi K, Kawai Y, Inoue R, Yamamoto Y, Matsumoto H, Matsuyama H.

Urol Int. 2017;99(4):446-452. doi: 10.1159/000477912. Epub 2017 Jun 21.

PMID:
28628910

Supplemental Content

Loading ...
Support Center